← Oncology Approval Tracker

FDA DECISION ·

Prevymis oral pellets

letermovir · Merck

FDA approvalNew formulationCytomegalovirus prevention after stem cell transplant
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Oral pellets to prevent cytomegalovirus infection and disease in seropositive allogeneic hematopoietic stem cell transplant recipients aged 6 months and older and weighing at least 6 kg. The formulation also has a separate kidney transplant indication.

LAMPGEN ANALYSIS

Why it matters

The pellet presentation adds an administration option when a transplant recipient cannot swallow a tablet.

What research teams should watch

Train caregivers on packet preparation and document formulation and weight at discharge to avoid a mismatch in home dosing.

PRIMARY RECORDS

Sources